MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

Trial Identifier: D7900C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03489525
Start Date: May 2018
Primary Completion Date: March 2022
Study Completion Date: March 2022
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Greek Translation
Spanish Translation

Trial Locations

Country Location
AU Adelaide, AU, 5000
AU East Melbourne, AU, 3002
AU Fitzroy, AU, 3065
AU Melbourne, AU, 3004
ES Badalona, ES, 08916
ES Barcelona, ES, 08036
ES Barcelona, ES, 08035
ES Gijón, ES, 33394
ES Madrid, ES, 28034
ES Pamplona, ES, 31008
ES Santander, ES, 39010
ES Valencia, ES, 46017
FR Angers, FR, 49933
FR NANTES, FR, 44093
FR Pessac, FR, 33600
FR Poitiers, FR, 86021
FR Toulouse Cedex 9, FR, 31059
FR Villejuif Cedex, FR, 94805
GR Athens, GR, 11528
US, AZ Phoenix, AZ, US, 85054
US, FL Jacksonville, FL, US, 32224
US, IN Indianapolis, IN, US, 46202
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02114
US, MI Detroit, MI, US, 48201
US, MN Rochester, MN, US, 55905
US, NC Charlotte, NC, US, 28204
US, VA Fairfax, VA, US, 22031